On July 31, 2025, Knight Therapeutics Inc. (TSX: GUD), a specialty pharmaceutical company operating in pan-America (excluding the USA), shared that its Brazilian subsidiary, United Medical Ltda., has filed a supplemental request to ANVISA, the Brazilian health regulatory body. The submission aims to secure approval for a new use of MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide. This application targets the treatment of adult patients who have previously undergone treatment for follicular lymphoma (FL). The supplementary application has been included in Project Orbis for review.